| association id |
FEATURE |
Drug id |
Propr |
Public |
Drug Name |
Drug Target |
N FEATURE pos |
N FEATURE neg |
log max Conc tested |
FEATURE neg logIC50 MEAN |
FEATURE pos logIC50 MEAN |
FEATURE deltaMEAN IC50 |
FEATURE IC50 effectSize |
FEATURE neg Glass delta |
FEATURE pos Glass delta |
ANOVA FEATURE pval |
Tissue ANOVA pval |
MSI ANOVA pval |
ANOVA FEATURE FDR % |
a45 |
gain_cnaPANCAN280_(ARID4B,FH) |
1003 |
1 |
1 |
Camptothecin |
TOP1 |
52 |
794 |
-2.3 |
-4.14 |
-2.53 |
1.61 |
0.92 . |
0.94 . |
0.76 . |
1.45e-07 |
9.27e-24 |
1.02e-01 |
0.053 |
a108 |
gain_cnaPANCAN275_(SDHC) |
1003 |
1 |
1 |
Camptothecin |
TOP1 |
44 |
802 |
-2.3 |
-4.12 |
-2.66 |
1.46 |
0.83 . |
0.84 . |
0.66 . |
1.69e-05 |
1.98e-23 |
1.04e-01 |
2.6 |
a276 |
gain_cnaPANCAN363_(ASXL1) |
1003 |
1 |
1 |
Camptothecin |
TOP1 |
85 |
761 |
-2.3 |
-4.14 |
-3.18 |
0.959 |
0.54 . |
0.54 . |
0.54 . |
1.93e-04 |
2.88e-23 |
1.05e-01 |
12 |
a316 |
gain_cnaPANCAN411_(BLM,CRTC3,FANCI,IDH2,NR2F2,PCSK6) |
1003 |
1 |
1 |
Camptothecin |
TOP1 |
22 |
824 |
-2.3 |
-4.09 |
-2.46 |
1.63 |
0.92 . |
0.93 . |
0.7 . |
2.81e-04 |
3.05e-23 |
1.06e-01 |
15 |
a321 |
gain_cnaPANCAN277_(DHX9) |
1003 |
1 |
1 |
Camptothecin |
TOP1 |
27 |
819 |
-2.3 |
-4.09 |
-2.68 |
1.4 |
0.79 . |
0.8 . |
0.64 . |
2.86e-04 |
3.06e-23 |
1.06e-01 |
15 |
a421 |
gain_cnaPANCAN213_(MCM3) |
1003 |
1 |
1 |
Camptothecin |
TOP1 |
47 |
799 |
-2.3 |
-4.1 |
-3.03 |
1.07 |
0.6 . |
0.62 . |
0.46 |
5.15e-04 |
3.35e-23 |
1.06e-01 |
20 |
a471 |
EWSR1-FLI1_mut |
1003 |
1 |
1 |
Camptothecin |
TOP1 |
16 |
830 |
-2.3 |
-4.01 |
-5.93 |
-1.92 |
1.1 * |
1.1 * |
1.2 * |
6.22e-04 |
3.45e-23 |
1.06e-01 |
22 |
